AAPL   316.73 (-0.68%)
FB   232.20 (-1.15%)
GOOGL   1,421.37 (+0.58%)
NVDA   348.71 (-3.42%)
BABA   201.72 (+1.01%)
AMD   53.19 (-3.59%)
T   30.82 (+3.15%)
ACB   15.61 (-2.50%)
F   5.84 (+3.36%)
GILD   73.18 (-0.22%)
DIS   120.95 (+2.48%)
NFLX   414.77 (-3.39%)
BA   144.73 (+5.24%)
AAPL   316.73 (-0.68%)
FB   232.20 (-1.15%)
GOOGL   1,421.37 (+0.58%)
NVDA   348.71 (-3.42%)
BABA   201.72 (+1.01%)
AMD   53.19 (-3.59%)
T   30.82 (+3.15%)
ACB   15.61 (-2.50%)
F   5.84 (+3.36%)
GILD   73.18 (-0.22%)
DIS   120.95 (+2.48%)
NFLX   414.77 (-3.39%)
BA   144.73 (+5.24%)
AAPL   316.73 (-0.68%)
FB   232.20 (-1.15%)
GOOGL   1,421.37 (+0.58%)
NVDA   348.71 (-3.42%)
BABA   201.72 (+1.01%)
AMD   53.19 (-3.59%)
T   30.82 (+3.15%)
ACB   15.61 (-2.50%)
F   5.84 (+3.36%)
GILD   73.18 (-0.22%)
DIS   120.95 (+2.48%)
NFLX   414.77 (-3.39%)
BA   144.73 (+5.24%)
AAPL   316.73 (-0.68%)
FB   232.20 (-1.15%)
GOOGL   1,421.37 (+0.58%)
NVDA   348.71 (-3.42%)
BABA   201.72 (+1.01%)
AMD   53.19 (-3.59%)
T   30.82 (+3.15%)
ACB   15.61 (-2.50%)
F   5.84 (+3.36%)
GILD   73.18 (-0.22%)
DIS   120.95 (+2.48%)
NFLX   414.77 (-3.39%)
BA   144.73 (+5.24%)
Log in

NASDAQ:ARAVAravive Stock Price, Forecast & News

$12.72
-0.05 (-0.39 %)
(As of 05/26/2020 04:00 PM ET)
Add
Compare
Today's Range
$12.50
Now: $12.72
$13.24
50-Day Range
$5.37
MA: $11.17
$14.30
52-Week Range
$3.34
Now: $12.72
$15.62
Volume133,197 shs
Average Volume155,204 shs
Market Capitalization$202.88 million
P/E RatioN/A
Dividend YieldN/A
Beta3.58
Aravive, Inc., a clinical stage biotechnology company, focuses on developing therapies for solid tumors and hematologic malignancies. Its lead candidate is AVB-S6-500, a soluble Fc-fusion protein, which is in Phase 1b/2 clinical trials for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, acute myeloid leukemia, triple negative breast cancer, and pancreatic cancer. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. is headquartered in Houston, Texas.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.60 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ARAV
CUSIPN/A
CIKN/A
Phone936-355-1910

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.75 million
Book Value$4.71 per share

Profitability

Net Income$-18,220,000.00

Miscellaneous

Employees14
Market Cap$202.88 million
Next Earnings Date8/5/2020 (Estimated)
OptionableOptionable

Receive ARAV News and Ratings via Email

Sign-up to receive the latest news and ratings for ARAV and its competitors with MarketBeat's FREE daily newsletter.

Aravive (NASDAQ:ARAV) Frequently Asked Questions

How has Aravive's stock been impacted by COVID-19 (Coronavirus)?

Aravive's stock was trading at $4.99 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ARAV shares have increased by 154.9% and is now trading at $12.72. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Aravive?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aravive in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Aravive.

When is Aravive's next earnings date?

Aravive is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Aravive.

How were Aravive's earnings last quarter?

Aravive Inc (NASDAQ:ARAV) posted its quarterly earnings results on Wednesday, May, 6th. The company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.36) by $0.36. View Aravive's earnings history.

What price target have analysts set for ARAV?

5 Wall Street analysts have issued 12-month target prices for Aravive's shares. Their forecasts range from $15.00 to $31.00. On average, they expect Aravive's stock price to reach $26.00 in the next twelve months. This suggests a possible upside of 104.4% from the stock's current price. View analysts' price targets for Aravive.

Has Aravive been receiving favorable news coverage?

Media headlines about ARAV stock have trended extremely negative this week, InfoTrie Sentiment reports. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Aravive earned a media sentiment score of -5.0 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutAravive.

Are investors shorting Aravive?

Aravive saw a decline in short interest in May. As of May 15th, there was short interest totaling 604,900 shares, a decline of 9.8% from the April 30th total of 670,800 shares. Based on an average daily volume of 173,500 shares, the short-interest ratio is currently 3.5 days. Approximately 7.1% of the shares of the company are sold short. View Aravive's Current Options Chain.

Who are some of Aravive's key competitors?

What other stocks do shareholders of Aravive own?

Who are Aravive's key executives?

Aravive's management team includes the following people:
  • Mr. Jay P. Shepard, Pres, CEO & Director (Age 61)
  • Dr. Jeffrey L. Cleland, Co-Founder (Age 54)
  • Dr. Joshua Silverman Ph.D., Co-Founder
  • Mr. Vinay Shah, Chief Financial Officer
  • Dr. Gail F. McIntyre, Chief Scientific Officer (Age 56)

What is Aravive's stock symbol?

Aravive trades on the NASDAQ under the ticker symbol "ARAV."

Who are Aravive's major shareholders?

Aravive's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (1.34%), Two Sigma Advisers LP (1.01%), Alpine Global Management LLC (1.03%), Two Sigma Investments LP (0.80%), Geode Capital Management LLC (0.55%) and UBS Group AG (0.53%). Company insiders that own Aravive stock include Jay Shepard, Kevin Haas and Srinivas Akkaraju. View institutional ownership trends for Aravive.

Which major investors are selling Aravive stock?

ARAV stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, BlackRock Inc., Morgan Stanley, and UBS Group AG. View insider buying and selling activity for Aravive.

Which major investors are buying Aravive stock?

ARAV stock was acquired by a variety of institutional investors in the last quarter, including Two Sigma Advisers LP, Alpine Global Management LLC, Connor Clark & Lunn Investment Management Ltd., Geode Capital Management LLC, Invesco Ltd., Wedbush Securities Inc., Jane Street Group LLC, and Acadian Asset Management LLC. View insider buying and selling activity for Aravive.

How do I buy shares of Aravive?

Shares of ARAV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Aravive's stock price today?

One share of ARAV stock can currently be purchased for approximately $12.72.

How big of a company is Aravive?

Aravive has a market capitalization of $202.88 million and generates $4.75 million in revenue each year. The company earns $-18,220,000.00 in net income (profit) each year or ($1.57) on an earnings per share basis. Aravive employs 14 workers across the globe.

What is Aravive's official website?

The official website for Aravive is www.aravive.com.

How can I contact Aravive?

Aravive's mailing address is River Oaks Tower3730 Kirby Drive Suite 1200, Houston TX, 77098. The company can be reached via phone at 936-355-1910 or via email at [email protected]

This page was last updated on 5/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.